Literature DB >> 1518837

Mutants of complement component C3 cleaved by the C4-specific C1-s protease.

P Mathias1, C J Carrillo, N E Zepf, N R Cooper, R T Ogata.   

Abstract

To identify some of the structural features determining specific protease recognition of complement components C3 and C4, we used site-specific mutagenesis to construct mutants of murine C3 that are cleaved by the C4-specific C1-s protease. Insertion of three amino acid residues corresponding to residues at the C1-s cleavage site of human C4 into murine C3 at the analogous C3 convertase cleavage site was adequate to render the mutant protein susceptible to C1-s cleavage. In addition, insertion of C3-specific residues at the same site or introduction of the C4-specific residues as substitutions rather than as an insertion also rendered the site susceptible to cleavage, but with 10- to 50-fold lower efficiencies, and insertion of even a single amino acid residue affected recognition by C1-s. Finally, insertion of amino acid residues into mC3 partially inhibited cleavage by the alternative-pathway C3 convertase, with insertion of C3- or C4-specific residues giving about the same level of inhibition. A simple interpretation of these data is that C1-s cleavage is dependent primarily on steric accessibility and on recognition of specific amino acid residues at the cleavage site, whereas C3 convertase cleavage is dependent primarily on specific interactions distal to the cleavage site, with only relatively weak, non-C3-specific interactions at the cleavage site itself.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1518837      PMCID: PMC49869          DOI: 10.1073/pnas.89.17.8125

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  A single arginine to tryptophan interchange at beta-chain residue 458 of human complement component C4 accounts for the defect in classical pathway C5 convertase activity of allotype C4A6. Implications for the location of a C5 binding site in C4.

Authors:  R O Ebanks; A S Jaikaran; M C Carroll; M J Anderson; R D Campbell; D E Isenman
Journal:  J Immunol       Date:  1992-05-01       Impact factor: 5.422

2.  Complete cDNA sequence of human complement pro-C5. Evidence of truncated transcripts derived from a single copy gene.

Authors:  D L Haviland; J C Haviland; D T Fleischer; A Hunt; R A Wetsel
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

3.  Human complement component C3: cDNA coding sequence and derived primary structure.

Authors:  M H de Bruijn; G H Fey
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

4.  Molecular characterization of the Ss and Slp (C4) proteins of the mouse H-2 complex: subunit composition, chain size polymorphism, and an intracellular (PRO-Ss) precursor.

Authors:  M H Roos; J P Atkinson; D C Shreffler
Journal:  J Immunol       Date:  1978-09       Impact factor: 5.422

5.  Structural and functional characterization of an incompletely processed form of murine C4 and Slp.

Authors:  D R Karp; J D Capra; J P Atkinson; D C Shreffler
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

6.  Complete cDNA sequence of the fourth component of murine complement.

Authors:  D S Sepich; D J Noonan; R T Ogata
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

7.  The structural basis of the multiple forms of human complement component C4.

Authors:  K T Belt; M C Carroll; R R Porter
Journal:  Cell       Date:  1984-04       Impact factor: 41.582

8.  Primary structure of the fifth component of murine complement.

Authors:  R A Wetsel; R T Ogata; B F Tack
Journal:  Biochemistry       Date:  1987-02-10       Impact factor: 3.162

9.  The role of the thioester bond in C3 and C4 in the determination of the conformational and functional states of the molecule.

Authors:  D E Isenman
Journal:  Ann N Y Acad Sci       Date:  1983       Impact factor: 5.691

10.  Structural and functional differences between the H-2 controlled Ss and Slp proteins.

Authors:  A Ferreira; V Nussenzweig; I Gigli
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.